• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

by Bellbrook Labs / Tuesday, 29 November 2022 / Published in Emerging Targets, HTS Assays, Innate Immunity, Neurodegenerative Diseases
SIRT2 Affects Neurodegenerative Diseases

Silent information regulator type 2 (Sirtuin 2 or SIRT2) is a highly evolutionarily conserved NAD+ dependent deacetylase. SIRT2 is the only Sirtuin that acts in the cytosol. It expresses in almost all tissues, but most abundantly in the central nervous system. While SIRT2 is classified as a type III histone deacetylase, it is also capable of performing this function on non-histone acetyllysine-bearing substrates. In addition, SIRT2 is capable of ADP-ribosylation, demyristoylase activity, and long-chain fatty acid deacylation.1

Structure & Function

The structure of SIRT2 consists of an N-terminal nuclear export sequence, a catalytic core, and a C-terminal nuclear import sequence. The catalytic core comprises a larger NAD+ binding Rossman fold domain hinged to a smaller zinc-binding domain. Together, these features create a large groove capable of interacting with NAD+ (Rossman domain) and negotiating protein-protein interactions between SIRT2 and its substrates (zinc-binding domain).2

Given its intracellular mobility, catalytic properties, and protein interactivity, SIRT2 has been found to participate in diverse cellular functions: DNA replication, transcription, & translation; epigenetic & post-translational modifications; genome integrity; autophagy; mitosis; lipid metabolism signaling; glucose metabolism signaling; inflammation; oxidative stress; cardiac & hepatic protection; and, most controversially, neurodegenerative diseases & cancer.3

Over the years, conflicting evidence both implicates and exonerates SIRT2 in neurological disorders and cancer. There are arguments for protective, coincidental, and causative aspects of SIRT2 in these disorders.4 Why should this be, and what could possibly disentangle these conflicting lines of evidence?

Isoforms of SIRT2

Currently, scientists identify 3 distinct SIRT2 isoforms. Isoforms 1 and 2 are fully functional deacetylases that can shuttle between the cytoplasm and the nucleus. Isoform 1, at 43 kDa, is expressed from all 16 exons of the SIRT2 gene and is predominantly found in skeletal muscle cytoplasm. Isoform 2, at 39 kDa, lacks expressed sequences from exons 1 through 3, predominantly exists in the fully mature central nervous system, and distributes across both the nucleus and cytoplasm. The missing first 37 amino acids of the full-length SIRT2 impair its ability to associate with chromatin.

Isoform 5 (murine isoform 3), at 36kDa, skips exons 2 through 4 and increasingly accumulates in aging central nervous tissue. Due to the omission of N-terminal amino acids 6 through 76, this splice variant lacks a functional nuclear export sequence (amino acids 41-51) and canonical catalytic capabilities, remaining confined to the nucleus.5 Isoform 5 does seem to confer epigenetic resistance to HBV infection.6

Looking Ahead

Could the key to resolving the conflicting roles of SIRT2 in disease depend upon which isoform is predominantly involved in a given disease state? Is it possible to reverse these diseases by silencing the prevailing isoform and inducing one that appropriately expresses in healthy tissue? Given the differing localizing and functional properties of the known isoforms, the particular SIRT2 splice variant present may be more important than the total amount of SIRT2 in a given tissue.

 

References

  1. Liu, Y. et al. (2020) Emerging Role of Sirtuin 2 in Parkinson’s Disease. Front. Aging Neurosci., 11:372, 1-11. Review. https://doi.org/10.3389/fnagi.2019.00372
  2. Zhang, F. and Li, B. (2022) Will Sirtuin 2 Be a Promising Target for Neuroinflammatory disorders? Front. Cell Neurosci., 16:915587, 1-13. Review. https://doi.org/10.3389/fncel.2022.915587
  3. Zhu, C. et al (2022) Multiple Roles of SIRT2 in Regulating Physiological and Pathological Signal Transduction. Hindawi Genetics Research, 2022:9282484, 1-14. Review. https://doi.org/10.1155/2022/9282484
  4. Wang, Y. et al. (2019) SIRT2: Controversy and multiple roles in disease and physiology. Ageing Research Review, 55(6):100961. Review. https://doi.org/10.1016/j.arr.2019.100961
  5. Eldridge, M. J. G. et al (2020) Active nuclear import of the deacetylase Sirtuin-2 is controlled by its C-terminus and importins. Nature Scientific Reports, 10:2034, 1-12. https://doi.org/10.1038/s41598-020-58397-6
  6. Piracha, Z. Z. et al (2020) An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases. Journal of Virology, 94(16)  https://doi.org/10.1128/JVI.00926-20
Tagged under: Innate Immunity, neurodegenerative disease, SIRT2, Sirtuin 2

What you can read next

A New Twist to Metastatic Spread
JAK1 Inhibitors for Autoimmune Disease
Battling Autoimmune Disorders Using JAK1 Inhibitors
Scientist Using a GTPase Assay
Researchers Employ GTPase Assay to Investigate Rab Proteins

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...
  • NSP16 Target for COVID-19 Therapeutics

    NSP16 Shows Promise for Anti-Viral Therapeutics

    SARS-CoV-2 virus (Covid-19) possesses one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP